The Experts below are selected from a list of 291 Experts worldwide ranked by ideXlab platform
Koji Uede - One of the best experts on this subject based on the ideXlab platform.
-
t1 and t2 Lip cancer a superselective method of facial arterial infusion therapy preliminary experience
Radiology, 1999Co-Authors: Kazushi Kishi, Masahiro Matsunaka, Morio Sato, Tetsuo Sonomura, Mikihisa Sakurane, Koji UedeAbstract:PURPOSE: To formulate and evaluate a facial arterial infusion chemotherapy for squamous cell Lip Carcinoma. MATERIALS AND METHODS: The study included six patients (age range, 46–84 years) with squamous cell Carcinoma of the lower Lip. There were two T1 tumors, three T2 tumors, and one T1-compatible postoperative recurrent tumor. A 4-F, double-lumen balloon catheter was inserted into the external carotid artery through the superficial temporal artery and placed for selective infusion into the tumor-feeding facial artery. Patients received a combination of mitomycin C (4.4 mg/m2 per body surface area) on day 1 and 3.2 mg/m2 of peplomycin sulfate on days 1–7 (22.4 mg/m2 per week), or, when peplomycin sulfate was contraindicated, 16 mg/m2 of cisplatin only on days 1–5 (80 mg/m2 per week). Two to three cycles of chemotherapy were given until tumor disappearance was histologically confirmed. RESULTS: Complete tumor disappearance was achieved in all cases. One patient had a self-limiting asthma attack during pep...
-
T1 and T2 Lip Cancer: A Superselective Method of Facial Arterial Infusion Therapy—Preliminary Experience
Radiology, 1999Co-Authors: Kazushi Kishi, Masahiro Matsunaka, Morio Sato, Tetsuo Sonomura, Mikihisa Sakurane, Koji UedeAbstract:PURPOSE: To formulate and evaluate a facial arterial infusion chemotherapy for squamous cell Lip Carcinoma. MATERIALS AND METHODS: The study included six patients (age range, 46–84 years) with squamous cell Carcinoma of the lower Lip. There were two T1 tumors, three T2 tumors, and one T1-compatible postoperative recurrent tumor. A 4-F, double-lumen balloon catheter was inserted into the external carotid artery through the superficial temporal artery and placed for selective infusion into the tumor-feeding facial artery. Patients received a combination of mitomycin C (4.4 mg/m2 per body surface area) on day 1 and 3.2 mg/m2 of peplomycin sulfate on days 1–7 (22.4 mg/m2 per week), or, when peplomycin sulfate was contraindicated, 16 mg/m2 of cisplatin only on days 1–5 (80 mg/m2 per week). Two to three cycles of chemotherapy were given until tumor disappearance was histologically confirmed. RESULTS: Complete tumor disappearance was achieved in all cases. One patient had a self-limiting asthma attack during pep...
Kazushi Kishi - One of the best experts on this subject based on the ideXlab platform.
-
t1 and t2 Lip cancer a superselective method of facial arterial infusion therapy preliminary experience
Radiology, 1999Co-Authors: Kazushi Kishi, Masahiro Matsunaka, Morio Sato, Tetsuo Sonomura, Mikihisa Sakurane, Koji UedeAbstract:PURPOSE: To formulate and evaluate a facial arterial infusion chemotherapy for squamous cell Lip Carcinoma. MATERIALS AND METHODS: The study included six patients (age range, 46–84 years) with squamous cell Carcinoma of the lower Lip. There were two T1 tumors, three T2 tumors, and one T1-compatible postoperative recurrent tumor. A 4-F, double-lumen balloon catheter was inserted into the external carotid artery through the superficial temporal artery and placed for selective infusion into the tumor-feeding facial artery. Patients received a combination of mitomycin C (4.4 mg/m2 per body surface area) on day 1 and 3.2 mg/m2 of peplomycin sulfate on days 1–7 (22.4 mg/m2 per week), or, when peplomycin sulfate was contraindicated, 16 mg/m2 of cisplatin only on days 1–5 (80 mg/m2 per week). Two to three cycles of chemotherapy were given until tumor disappearance was histologically confirmed. RESULTS: Complete tumor disappearance was achieved in all cases. One patient had a self-limiting asthma attack during pep...
-
T1 and T2 Lip Cancer: A Superselective Method of Facial Arterial Infusion Therapy—Preliminary Experience
Radiology, 1999Co-Authors: Kazushi Kishi, Masahiro Matsunaka, Morio Sato, Tetsuo Sonomura, Mikihisa Sakurane, Koji UedeAbstract:PURPOSE: To formulate and evaluate a facial arterial infusion chemotherapy for squamous cell Lip Carcinoma. MATERIALS AND METHODS: The study included six patients (age range, 46–84 years) with squamous cell Carcinoma of the lower Lip. There were two T1 tumors, three T2 tumors, and one T1-compatible postoperative recurrent tumor. A 4-F, double-lumen balloon catheter was inserted into the external carotid artery through the superficial temporal artery and placed for selective infusion into the tumor-feeding facial artery. Patients received a combination of mitomycin C (4.4 mg/m2 per body surface area) on day 1 and 3.2 mg/m2 of peplomycin sulfate on days 1–7 (22.4 mg/m2 per week), or, when peplomycin sulfate was contraindicated, 16 mg/m2 of cisplatin only on days 1–5 (80 mg/m2 per week). Two to three cycles of chemotherapy were given until tumor disappearance was histologically confirmed. RESULTS: Complete tumor disappearance was achieved in all cases. One patient had a self-limiting asthma attack during pep...
Ali şefik Hosal - One of the best experts on this subject based on the ideXlab platform.
-
the role of suprahyoid neck dissection in the treatment of squamous cell Carcinoma of the lower Lip 20 years experience at a tertiary center
Journal of Cranio-maxillofacial Surgery, 2016Co-Authors: Oguz Kuscu, Munir Demir Bajin, Nilda Suslu, Ali şefik HosalAbstract:Abstract Purpose To evaluate the efficacy of L1–2ND in the management of the lower Lip squamous cell Carcinoma and to achieve the highest cure rates with adequate neck dissection. Methods A retrospective review was completed on patients treated between 1994 and 2014. The case histories of 184 patients who were treated with surgical excision of the primary tumor along with neck dissection, and 24 patients who were treated only with surgical excision without neck dissection at another center, were studied. All patients were followed up for evidence of recurrent disease. Results In 208 patients (193 men, 15 women) with a mean age of 51 years, 12 were N1, 3 were N2, and 169 were N0; 24 patients had undergone operation at another center without neck dissection. Lymph node metastases were present in 34 patients (18.4%) with dissected necks and occult metastases were detected in 19 patients with clinically N0 necks (11.2%). The median follow-up of each patient was 28 months. Only 1 patient developed neck recurrence, and there was no local recurrence. The overall survival rate (OAS) of patients with clinical N0 disease who underwent neck dissection was 94.7%; the OAS of the patients who were not treated with neck dissection was 29.1%. Conclusion Level 1–2 neck dissection (L1–2ND) is the treatment of choice for controlling neck disease in patients with lower Lip Carcinoma, and serves as a staging procedure to detect patients who require adjuvant therapy.
Mikihisa Sakurane - One of the best experts on this subject based on the ideXlab platform.
-
t1 and t2 Lip cancer a superselective method of facial arterial infusion therapy preliminary experience
Radiology, 1999Co-Authors: Kazushi Kishi, Masahiro Matsunaka, Morio Sato, Tetsuo Sonomura, Mikihisa Sakurane, Koji UedeAbstract:PURPOSE: To formulate and evaluate a facial arterial infusion chemotherapy for squamous cell Lip Carcinoma. MATERIALS AND METHODS: The study included six patients (age range, 46–84 years) with squamous cell Carcinoma of the lower Lip. There were two T1 tumors, three T2 tumors, and one T1-compatible postoperative recurrent tumor. A 4-F, double-lumen balloon catheter was inserted into the external carotid artery through the superficial temporal artery and placed for selective infusion into the tumor-feeding facial artery. Patients received a combination of mitomycin C (4.4 mg/m2 per body surface area) on day 1 and 3.2 mg/m2 of peplomycin sulfate on days 1–7 (22.4 mg/m2 per week), or, when peplomycin sulfate was contraindicated, 16 mg/m2 of cisplatin only on days 1–5 (80 mg/m2 per week). Two to three cycles of chemotherapy were given until tumor disappearance was histologically confirmed. RESULTS: Complete tumor disappearance was achieved in all cases. One patient had a self-limiting asthma attack during pep...
-
T1 and T2 Lip Cancer: A Superselective Method of Facial Arterial Infusion Therapy—Preliminary Experience
Radiology, 1999Co-Authors: Kazushi Kishi, Masahiro Matsunaka, Morio Sato, Tetsuo Sonomura, Mikihisa Sakurane, Koji UedeAbstract:PURPOSE: To formulate and evaluate a facial arterial infusion chemotherapy for squamous cell Lip Carcinoma. MATERIALS AND METHODS: The study included six patients (age range, 46–84 years) with squamous cell Carcinoma of the lower Lip. There were two T1 tumors, three T2 tumors, and one T1-compatible postoperative recurrent tumor. A 4-F, double-lumen balloon catheter was inserted into the external carotid artery through the superficial temporal artery and placed for selective infusion into the tumor-feeding facial artery. Patients received a combination of mitomycin C (4.4 mg/m2 per body surface area) on day 1 and 3.2 mg/m2 of peplomycin sulfate on days 1–7 (22.4 mg/m2 per week), or, when peplomycin sulfate was contraindicated, 16 mg/m2 of cisplatin only on days 1–5 (80 mg/m2 per week). Two to three cycles of chemotherapy were given until tumor disappearance was histologically confirmed. RESULTS: Complete tumor disappearance was achieved in all cases. One patient had a self-limiting asthma attack during pep...
Tetsuo Sonomura - One of the best experts on this subject based on the ideXlab platform.
-
t1 and t2 Lip cancer a superselective method of facial arterial infusion therapy preliminary experience
Radiology, 1999Co-Authors: Kazushi Kishi, Masahiro Matsunaka, Morio Sato, Tetsuo Sonomura, Mikihisa Sakurane, Koji UedeAbstract:PURPOSE: To formulate and evaluate a facial arterial infusion chemotherapy for squamous cell Lip Carcinoma. MATERIALS AND METHODS: The study included six patients (age range, 46–84 years) with squamous cell Carcinoma of the lower Lip. There were two T1 tumors, three T2 tumors, and one T1-compatible postoperative recurrent tumor. A 4-F, double-lumen balloon catheter was inserted into the external carotid artery through the superficial temporal artery and placed for selective infusion into the tumor-feeding facial artery. Patients received a combination of mitomycin C (4.4 mg/m2 per body surface area) on day 1 and 3.2 mg/m2 of peplomycin sulfate on days 1–7 (22.4 mg/m2 per week), or, when peplomycin sulfate was contraindicated, 16 mg/m2 of cisplatin only on days 1–5 (80 mg/m2 per week). Two to three cycles of chemotherapy were given until tumor disappearance was histologically confirmed. RESULTS: Complete tumor disappearance was achieved in all cases. One patient had a self-limiting asthma attack during pep...
-
T1 and T2 Lip Cancer: A Superselective Method of Facial Arterial Infusion Therapy—Preliminary Experience
Radiology, 1999Co-Authors: Kazushi Kishi, Masahiro Matsunaka, Morio Sato, Tetsuo Sonomura, Mikihisa Sakurane, Koji UedeAbstract:PURPOSE: To formulate and evaluate a facial arterial infusion chemotherapy for squamous cell Lip Carcinoma. MATERIALS AND METHODS: The study included six patients (age range, 46–84 years) with squamous cell Carcinoma of the lower Lip. There were two T1 tumors, three T2 tumors, and one T1-compatible postoperative recurrent tumor. A 4-F, double-lumen balloon catheter was inserted into the external carotid artery through the superficial temporal artery and placed for selective infusion into the tumor-feeding facial artery. Patients received a combination of mitomycin C (4.4 mg/m2 per body surface area) on day 1 and 3.2 mg/m2 of peplomycin sulfate on days 1–7 (22.4 mg/m2 per week), or, when peplomycin sulfate was contraindicated, 16 mg/m2 of cisplatin only on days 1–5 (80 mg/m2 per week). Two to three cycles of chemotherapy were given until tumor disappearance was histologically confirmed. RESULTS: Complete tumor disappearance was achieved in all cases. One patient had a self-limiting asthma attack during pep...